| Literature DB >> 32460817 |
Chen Hu1, Yu Bai2, Jun Li1, Guoyin Zhang1, Libo Yang1, Chengwei Bi1, Bin Zhao1, Yong Yang1, Ruiqian Li1, Hongyi Wu1, Qilin Wang1, Yang Qin1.
Abstract
BACKGROUND: Penile squamous cell carcinoma (PSCC) represents an important public health problem for developing countries. The major prognostic factors in PSCC are pathological subtype, perineural invasion, lymphovascular invasion, depth of invasion and grade, which are hard to obtain precisely before the operation. Besides, micro-metastases will be detected in about 30% of intermediate-risk patients with clinically non-palpable inguinal lymph nodes after inguinal lymph node dissection (ILND). It means approximately 70% of patients are unable to benefit from ILND who might suffered from the complications of surgery. We hope some biomarkers could be found which are able to predict the outcome before surgery and reflect the inguinal lymph nodes metastasis.Entities:
Keywords: LDH; LMR; NLR; PLR; Penile cancer
Mesh:
Substances:
Year: 2020 PMID: 32460817 PMCID: PMC7251912 DOI: 10.1186/s12894-020-00628-z
Source DB: PubMed Journal: BMC Urol ISSN: 1471-2490 Impact factor: 2.264
Patients’ characteristics
| Variable | NLR | LMR | PLR | LDH | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | NLR≤2.94 | NLR>2.94 | p | LMR≤4.74 | LMR>4.74 | p | PLR≤133.5 | PLR>133.5 | p | LDH≤188.5 | LDH>188.5 | p | |
| Age, y | 0.296 | 0.169 | 0.566 | 0.184 | |||||||||
| <53 | 140 | 103 | 37 | 55 | 85 | 105 | 35 | 115 | 25 | ||||
| ≥53 | 85 | 54 | 31 | 45 | 40 | 55 | 30 | 65 | 20 | ||||
| Tumor type | 0.026 | 0.091 | 0.131 | 0.943 | |||||||||
| benign | 44 | 35 | 9 | 17 | 27 | 38 | 6 | 35 | 9 | ||||
| well | 96 | 69 | 27 | 39 | 57 | 62 | 34 | 79 | 17 | ||||
| moderate | 74 | 49 | 25 | 35 | 39 | 52 | 22 | 59 | 15 | ||||
| poor | 8 | 4 | 4 | 7 | 1 | 6 | 2 | 6 | 2 | ||||
| others | 3 | 0 | 3 | 2 | 1 | 2 | 1 | 2 | 1 | ||||
| Anatomic stage | 0.002 | 0.063 | 0.005 | 0.076 | |||||||||
| 0 | 44 | 33 | 9 | 17 | 25 | 36 | 6 | 33 | 9 | ||||
| I | 67 | 51 | 16 | 23 | 44 | 48 | 19 | 57 | 10 | ||||
| II | 39 | 28 | 11 | 18 | 21 | 31 | 8 | 33 | 6 | ||||
| III | 62 | 41 | 21 | 31 | 31 | 39 | 22 | 50 | 12 | ||||
| IV | 15 | 4 | 11 | 11 | 4 | 6 | 9 | 8 | 7 | ||||
| N stage | 0.001 | 0.024 | 0.009 | 0.053 | |||||||||
| 0 | 148 | 112 | 36 | 58 | 90 | 115 | 33 | 123 | 25 | ||||
| 1 | 28 | 15 | 13 | 18 | 10 | 15 | 13 | 24 | 4 | ||||
| 2 | 36 | 26 | 10 | 15 | 21 | 24 | 12 | 27 | 9 | ||||
| 3 | 13 | 4 | 9 | 9 | 4 | 6 | 7 | 7 | 6 | ||||
| M | 0.008 | 0.051 | 0.146 | 0.545 | |||||||||
| 0 | 222 | 157 | 65 | 97 | 125 | 159 | 63 | 179 | 43 | ||||
| 1 | 3 | 0 | 3 | 3 | 0 | 1 | 2 | 2 | 1 | ||||
| Initial treatment | 0.004 | 0.094 | 0.863 | 0.052 | |||||||||
| surveillance | 23 | 10 | 13 | 14 | 9 | 16 | 7 | 15 | 8 | ||||
| surgery | 225 | 147 | 55 | 85 | 116 | 144 | 59 | 166 | 36 | ||||
| Recurrence | 0.01 | 0.635 | 0.004 | 0.235 | |||||||||
| no | 150 | 113 | 37 | 65 | 85 | 116 | 34 | 124 | 26 | ||||
| yes | 75 | 44 | 31 | 35 | 40 | 44 | 31 | 57 | 18 | ||||
| Vital status | 0.000 | 0.001 | 0 | 0.003 | |||||||||
| Alive | 171 | 131 | 40 | 65 | 106 | 134 | 37 | 145 | 26 | ||||
| Dead | 54 | 26 | 28 | 35 | 19 | 26 | 28 | 36 | 18 | ||||
Fig. 1KaplanMeier curve of NLR for overall survival (OS)
Fig. 2KaplanMeier curve of NLR for progression free survival (PFS)
Fig. 3KaplanMeier curve of LMR for overall survival (OS) and 4
Fig. 4KaplanMeier curve of LMR for progression free survival (PFS)
Fig. 5KaplanMeier curve of PLR for overall survival (OS)
Fig. 6KaplanMeier curve of PLR for progression free survival (PFS)
Fig. 7KaplanMeier curve of LDH for overall survival (OS)
Fig. 8KaplanMeier curve of LDH for progression free survival (PFS)
Cox regression model for OS and PFS
| Variables | OS | PFS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | |||||||||
| HR | 95%CI | p | HR | 95%CI | p | HR | 95%CI | p | HR | 95%CI | p | |
| <53 | reference | 1.077-3.174 | 0.026 | reference | 1.055-3.983 | 0.035 | reference | 0.785-1.974 | 0.352 | |||
| ≥53 | 1.849 | 1.961 | 1.245 | |||||||||
| benign tumor | reference | 0.002 | reference | 0.205 | reference | 0.006 | reference | 0.135 | ||||
| Well | 0.97 | 0.021-0.448 | 0.305 | 0.054-1.715 | 0.046 | 0.039-0.970 | 0.405 | 0.075-2.186 | ||||
| moderate | 0.211 | 0.060-0.737 | 0.22 | 0.052-0.938 | 0.332 | 0.116-2.070 | 0.51 | 0.111-2.336 | ||||
| poor | 0.447 | 0.130-1.541 | 0.419 | 0.106-1.655 | 0.868 | 0.211-3.716 | 0.895 | 0.201-3.982 | ||||
| others | 0.594 | 0.130-2.719 | 0.265 | 0.051-1.378 | 0.646 | 0.109-3.944 | 0.301 | 0.043-2.112 | ||||
| negigitve | reference | 5.243-20.918 | 0.000 | reference | 3.224-15.784 | 0.000 | reference | 3.096-8.080 | 0.000 | reference | 2.198-6.250 | 0.000 |
| positive | 10.472 | 7.133 | 5.002 | 3.706 | ||||||||
| 0 | reference | 6.637-85.927 | 0.000 | reference | 2.223-40.238 | 0.002 | reference | 2.484-26.505 | 0.001 | reference | 1.184-18.072 | 0.028 |
| 1 | 23.881 | 9.458 | 8.114 | 4.626 | ||||||||
| surveillance | reference | 0.222-0.937 | 0.033 | reference | 0.18-1.006 | 0.052 | reference | 0.345-1.307 | 0.241 | |||
| surgery | 0.456 | 0.425 | 0.671 | |||||||||
| low NLR | reference | 1.739-5.064 | 0.000 | reference | 0.605-2.718 | 0.516 | reference | 1.226-3.081 | 0.005 | reference | 0.679-1.966 | 0.594 |
| high NLR | 2.967 | 1.283 | 1.944 | 1.115 | ||||||||
| low LMR | reference | 0.025-0.689 | 0.001 | reference | 0.448-2.164 | 0.97 | reference | 0.553-1.372 | 0.871 | |||
| high LMR | 0.394 | 0.985 | 0.551 | |||||||||
| low PLR | reference | 2.011-5.881 | 0.000 | reference | 1.644-6.171 | 0.001 | reference | 1.384-3.478 | 0.001 | reference | 1.104-3.242 | 0.02 |
| high PLR | 3.439 | 3.186 | 2.194 | 1.892 | ||||||||
| low LDH | reference | 1.267-4.002 | 0.006 | reference | 1.051-3.808 | 0.035 | reference | 0.859-2.487 | 0.162 | |||
| high LDH | 2.252 | 2 | 1.462 | |||||||||